



June 26, 2024
JCR Pharmaceuticals Co., Ltd.

Translation

Matters Concerning Controlling Shareholders (Affiliated Companies)

June 26, 2024--JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announces, with respect to MEDIPAL HOLDINGS CORPORATION, our affiliated company concerning the controlling shareholders that are described below.

1. Trade names of the parent company, controlling shareholders (excluding the parent company) or other affiliated companies

(As of March 31, 2024)

Name	Attribution	Voting rights Ownership ratio (%)			Financial instruments exchange on which the outstanding shares are listed
		Direct ownership	Collective ownership	Total	
MEDIPAL HOLDINGS CORPORATION	Other affiliated company	23.28	-	23.28	The Prime Market on the Tokyo Stock Exchange

2. The positioning of the listed company in the corporate group of the parent company and relations with other listed companies and the parent company

MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) is the largest shareholder of JCR (voting rights ownership of 23.28%) and is an “other affiliated company.”

JCR and MEDIPAL concluded a business alliance agreement on September 21, 2017 with the aim to further enhance the corporate values of both companies, propel their continuous growth, and to effectively and efficiently leverage MEDIPAL’s strengths in distribution and sales promotion, and JCR’s strengths in pharmaceutical research and development.

Furthermore, in October 2022, JCR granted MEDIPAL concluded a Memorandum, through which JCR granted MEDIPAL the exclusive negotiation rights for the global commercialization outside Japan of four new drug candidates developed by JCR, targeting ultra-rare lysosomal storage diseases (hereinafter, “the Memorandum”). In accordance with the Memorandum, JCR concluded a licensing agreement with MEDIPAL for a therapeutic candidate for the treatment of fucosidosis. In September 2023, the two companies entered into a licensing agreement for the overseas commercialization of JR-446, a therapeutic drug targeting mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B), and a partnership agreement for the joint development and commercialization of JR-446 in Japan.

As regards business activities and management decisions, MEDIPAL makes its own decisions and executes operations independently, under the responsibilities of the JCR, and the JCR recognizes that our independence is secured.

(Other positions held by officers)

(As of June 26, 2024)

Title	Name	Title at the group company such as parent company
Outside Director	Toshihide Yoda	<ul style="list-style-type: none">• Senior Managing Director, In charge of IR General Manager of Business Development Department Division, MEDIPAL HOLDINGS CORPORATION• Director of JCR USA, Inc.

3. Matters concerning transactions with the controlling shareholders

Fiscal year ended March 31, 2024 (April 1, 2023 – March 31, 2024)

Company name	Location	Paid-in Capital (millions of yen)	Business	Ratio of holding (held) voting rights, etc. (%)	Relationship with the related party	Content of transaction	transaction amount (millions of yen)	Account title	Balance, end of period (millions of yen)
MEDIPAL HOLDINGS CORPORATION	Chuo-ku, Tokyo	22,398	Control, management and support of affiliated companies as a holding company	—% (23.5%)	Development investment contract	product sales*	4,000	others Non-current liabilities	82

* Prices and other transaction terms are determined through negotiations and are the same as those for third-party transactions.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###